Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective, observational study
To investigate the effectiveness and safety of 3  mg drospirenone and 20 μg ethinyl estradiol tablet (3 mg DRSP/20 μg EE) in the treatment of polycystic ovary syndrome (PCOS). (Source: BMC Women's Health)
Source: BMC Women's Health - February 27, 2020 Category: OBGYN Authors: Li Li, Ruiqin Zhang, Jing Zeng, Hu Ke, Xiuhong Peng, Liying Huang, Hongmei Zhang, Zhijing Chen, Tian Tian Li, Qiuxiao Tan, Ying Yang, Xiaofang Li and Xin Li Tags: Research article Source Type: research

Safety and Efficacy of Combined Oral Contraceptive Ethinyl Estradiol/Drospirenone (YAZ) in Chinese Women: A Single-Arm, Open-Label, Multicenter, Post-Authorization Study
AbstractIntroductionThe study was conducted to assess the safety and efficacy of a combined oral contraceptive, YAZ, containing 3  mg drospirenone/20 μg ethinyl estradiol administered in a 24/4 regimen.MethodsThis was a single-arm, open-label, interventional, post-authorization safety surveillance study of YAZ across 6 treatment cycles. Primary objective was assessing its safety profile in Chinese women. Secondary objectives included assessing contraceptive efficacy, cycle control, and bleeding patterns among subjects with and without preceding abortion, along with efficacy in moderate acne vulgaris. Subgroup ...
Source: Advances in Therapy - January 16, 2020 Category: Drugs & Pharmacology Source Type: research

Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
Date: February 10, 2020 Issue #:  1591Summary:  The FDA has approved a progestin-only oral contraceptive ( " minipill " ) containing drospirenone (Slynd– Exeltis). All other progestin-only oral contraceptives available in the US contain norethindrone (Camila, and others). Progestin-only oral contraceptives are similar in efficacy to combination oral contraceptives. They are used predominantly by breastfeeding women and by those in whom estrogen is poorly tolerated or contraindicated. Combination oral contraceptives containing drospirenone and ethinyl estradiol have been availabl...
Source: The Medical Letter - January 2, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research

Pregnancy after mumps: a case report
ConclusionLow-dose contraceptive treatment containing progesterone, followed by Drospil, which includes both estradiol and progesterone, had a synergistic effect that led to the growth of the patient ’s uterus. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - December 22, 2019 Category: General Medicine Source Type: research

Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females
To determine the pharmacokinetics (PK) of drospirenone (DRSP), alone versus in combination with ethinyl estradiol (EE), after single and repeated administration.Study designWe conducted a single-centre, open-label, crossover, 2-treatment, 2-period, 2-sequence study in which non-micronized DRSP 4 mg or a combination of DRSP 3 mg and EE 0.02 mg were administered to healthy female subjects on day 1 to obtain a single-dose kinetic profile, and from day 4 to day 15 to obtain a repeated-dose kinetic profile. (Source: Contraception)
Source: Contraception - November 20, 2019 Category: OBGYN Authors: W.H. Richter, R. Koytchev, V. Kirkov, G. Merki, E. Colli, P.-A. Regidor Tags: Original Research Article Source Type: research

Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone)
AbstractIntroductionPolycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 5 –10% of women of reproductive age. It is characterized by chronic anovulation leading to menstrual disorders, and increased infertility. The syndrome can also manifest as hirsutism and acne.Aim of the studyThe aim of the study was to compare, over a duration of 6 months, the effects of drospirenone (DRSP) versus chlormadinone acetate (CMA) containing oral contraceptives (OCs) on clinical, hormonal, and metabolic parameters in 120 PCOS women.Materials and methods120 women with the diagnosis of PCOS according to the Rotterda...
Source: Journal of Endocrinological Investigation - October 25, 2019 Category: Endocrinology Source Type: research

Bone health in estrogen-free contraception
This article reviews the effect of estrogens and progestogens on bone and presents new data of the currently approved drospirenone-only pill. The use of progestin-only contraceptives leading to an estradiol level between 30 and 50 pg/ml does not seem to lead to an acc elerate bone loss. (Source: Osteoporosis International)
Source: Osteoporosis International - August 24, 2019 Category: Orthopaedics Source Type: research

A high resolution LC–MS targeted method for the concomitant analysis of 11 contraceptive progestins and 4 steroids
Publication date: 25 October 2019Source: Journal of Pharmaceutical and Biomedical Analysis, Volume 175Author(s): Csaba Ferenc Laszlo, Jonathan Paz Montoya, Marie Shamseddin, Fabio De Martino, Alexandre Beguin, Rene Nellen, Stephen James Bruce, Marc Moniatte, Hugues Henry, Cathrin BriskenAbstractIn the context of hormonal contraception and hormone replacement therapy (HRT), many women are exposed to exogenous hormones. Current use of hormonal contraception with combined ethinyl estradiol and different progestins bestows a breast cancer relative risk (RR) of 1.2- while combined HRT has a RR of 2. Although these exposures pre...
Source: Journal of Pharmaceutical and Biomedical Analysis - August 5, 2019 Category: Drugs & Pharmacology Source Type: research

Drospirenone-containing contraceptive exerts positive effects on cardiac uric acid and PAI-1 but not GSK-3: Improved safety profiles in contraception?
Publication date: Available online 6 June 2019Source: PathophysiologyAuthor(s): Oluwaseun A. Adeyanju, Olaniyi A. Soetan, Lawrence A. OlatunjiAbstractThe use of combined oral contraceptives (COC) have been associated with increased risk of adverse cardiovascular events and elevated cardiac and circulating plasminogen activator inhibitor-1 (PAI-1) and glycogen synthase kinase-3 (GSK-3) have been implicated in these events. Contraceptives containing drospirenone, a progestin with anti-androgenic actions may have a positive or neutral effect on cardiac PAI-1 and GSK-3 levels. Studies on the favorable effects of oral contracep...
Source: Pathophysiology - June 6, 2019 Category: Pathology Source Type: research

Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
Date: July 1, 2019 Issue #:  1575Summary:  The FDA has approvedBijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an intact uterus. The manufacturer is marketingBijuva as " the first and only FDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule " . (Source: The Medical Letter)
Source: The Medical Letter - May 29, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Activella Alora Angeliq bazedoxifene Bijuva Bioidentical Hormones Climara Combi-Patch Divigel Drospirenone Duavee Elestrin Estrogens Evamist femhrt Femring Hot flashes Medroxyprogesterone Menest Menopause Premarin Source Type: research

Effects of drospirenone and norethisterone acetate combined with estradiol on mammographic density and proliferation of breast epithelial cells - a prospective randomized trial
Long-term menopausal hormone treatment (MHT) has been associated with an increased risk of breast cancer [1]. This knowledge has resulted in a dramatic decline in the use of MHT during the last fifteen years. Still there are many women who request MHT for the alleviation of postmenopausal symptoms. Several factors have been identified to influence the risk of breast cancer, including breast tissue density as shown either by mammography or histology [2]. (Source: Maturitas)
Source: Maturitas - April 4, 2019 Category: Primary Care Authors: Angelica Lind én Hirschberg, Edneia Tani, Kerstin Brismar, Eva Lundström Source Type: research

combined oral contraceptive IN FEMALE MICE CAUSES HYPERINSULINEMIA DUE TO β-cell HYPERSECRETION AND REDUCTION IN INSULIN CLEARANCE
Publication date: Available online 25 March 2019Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Cremilda Amaral Roso de Oliveira, Thiago dos Reis Araujo, Gésily de Souza Aguiar, Joel Alves da Silva Junior, Jean Franciesco Vettorazzi, Israelle Netto Freitas, Kênia Moreno de Oliveira, Antonio Carlos Boschero, Maria Lúcia Bonfleur, Júlia Rosauro Clarke, Helene Nara Henriques, Rosane Aparecida RibeiroAbstractOral contraception is the most commonly used interventional method in the world. However, several women employ the continuous use of these hormones to avoid pre- and m...
Source: The Journal of Steroid Biochemistry and Molecular Biology - March 26, 2019 Category: Biochemistry Source Type: research

Birth Control Pills and Thrombotic Risks: Differences of Contraception Methods with and without Estrogen.
Abstract In Germany one-third of the women in fertile age use combined oral contraceptives (COCs), which consist mostly of ethinylestradiol (EE) and a synthetic progestin. Older COCs with norethisterone or levonorgestrel have a lower risk for venous thromboembolism (VTE) than newer COCs with desogestrel, drospirenone, or gestodene. This is also true for nonoral combined hormonal contraceptives. The risk of newer COCs containing estradiol instead of EE is not clear due to missing data. Progestin-only hormonal contraception is not associated with a significant increase of the risk for VTE with the exception of depot...
Source: Hamostaseologie - January 22, 2019 Category: Hematology Authors: Rott H Tags: Hamostaseologie Source Type: research

Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa
AbstractThis paper reviews past and current progress in developing pharmacologic agents for the treatment of individuals with bulimia nervosa (BN). We searched the literature and clinical trial registries for compounds studied in BN, the related condition, binge eating disorder (BED), and preclinical models of binge-eating behavior. Drug classes evaluated included antidepressants, antiepileptic drugs, stimulants and other medications for attention-deficit/hyperactivity disorder, opioid antagonists, and weight loss agents, among others. The only available drugs with established efficacy in BN at this time include antidepres...
Source: CNS Drugs - December 6, 2018 Category: Neurology Source Type: research

The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients.
Authors: Lim S, Kim YH, Lee KB, Lee JM Abstract OBJECTIVE: To determine whether drospirenone/estradiol (DRSP/E2) has an adverse effect on clinical outcomes in surgically staged International Federation of Gynecology and Obstetrics (FIGO) stage I/II endometrial cancer (EC) patients. METHODS: In a retrospective case-controlled study, 58 women with EC who had received DRSP/E2 postoperatively were compared with 116 women who had not. And, oncologic safety of postoperative hormone therapy with DRSP/E2 in EC survivors were compared between the 2 groups after propensity score matching using a logistic regression model...
Source: Journal of Gynecologic Oncology - July 21, 2018 Category: OBGYN Tags: J Gynecol Oncol Source Type: research

The effects of different therapeutic modalities on cardiovascular risk factors in women with polycyst ıc ovary syndrome: A randomızed controlled study
This study was designed to evaluate the effects of 3  mg drospirenone/30 μg ethinyl estradiol (OC) alone or combined with 1700 mg metformin on metabolic risk factors. (Source: Taiwanese Journal of Obstetrics and Gynecology)
Source: Taiwanese Journal of Obstetrics and Gynecology - June 1, 2018 Category: OBGYN Authors: Serkan Bodur, Ozgur Dundar, Mine Kanat-Pektas, Mehmet Ferdi Kinci, Levent Tutuncu Tags: Original Article Source Type: research

A comparison of two different oral contraceptives in patients with severe primary dysmenorrhoea.
In this study, although there was no superiority in pain relief between the treatment groups, lower VAS scores and lower RI values of uterine arteries were seen after treatment. Both OCPs relieve pain in severe PD. There was no serious adverse effect in the patients. What the implications are of these findings for clinical practice and/or further research: Estradiol valerate/dienogest, which is a routinely prescribed drug for heavy menstrual bleeding in women who desire oral contraception, is as effective as ethinylestradiol/drospirenone in pain relief. PMID: 29537325 [PubMed - as supplied by publisher] (Source: Journa...
Source: Journal of Obstetrics and Gynaecology - March 17, 2018 Category: OBGYN Tags: J Obstet Gynaecol Source Type: research

[Customization of hormonal contraception].
Authors: DE Leo V, Cianci A, DI Carlo C, Cappelli V, Fruzzetti F Abstract In the last few years new oral contraceptives have been marketed showing a better safety profile for women. They are the result of important changes made to the old compounds. As far as the estrogenic component, with the aim of decreasing side effects, the dose of ethinyl estradiol has been reduced and synthetic estrogens have been replaced by natural estradiol, further improving the safety profile. Also the progestin component in the last years has been changed in terms of dose, endocrine and metabolic characteristics. Levonorgestrel is an a...
Source: Minerva Ginecologica - January 20, 2018 Category: OBGYN Tags: Minerva Ginecol Source Type: research

Simultaneous total occlusion of two coronary arteries associated with use of drospirenone-ethinyl estradiol (oral contraceptive).
In this report, a 33-year-old woman who had used drospirenone-ethinyl estradiol for 6 months was admitted with MI and symptoms of cardiogenic shock. Coronary angiography revealed the total occlusion of 2 coronary arteries and so percutaneous coronary intervention was performed. To the best of our knowledge, this is the first case report of simultaneous total occlusion of 2 coronary arteries associated with the use of drospirenone-ethinyl estradiol in the English-language medical literature. PMID: 29339693 [PubMed - in process] (Source: Turk Kardiyoloji Dernegi arsivi)
Source: Turk Kardiyoloji Dernegi arsivi - January 1, 2018 Category: Cardiology Authors: Atmaca H, Köprülü D, Kiriş T, Zeren G, Şahin İ Tags: Turk Kardiyol Dern Ars Source Type: research

Endocrine disruptors affect larval zebrafish behavior: Testing potential mechanisms and comparisons of behavioral sensitivity to alternative biomarkers
Publication date: Available online 6 October 2017 Source:Aquatic Toxicology Author(s): Thomas W.K. Fraser, Abdolrahman Khezri, Anna M. Lewandowska-Sabat, Theodore Henry, Erik Ropstad Larval zebrafish (Danio rerio) are a tool for assessing endocrine disruption during early development. Here, we investigated the extent to which a simple light/dark behavioral test at five days post fertilization could compliment current methods within the field. We exposed fertilized embryos to hormones (17β-estradiol, testosterone, dihydrotestosterone, 11-ketotestosterone, thyroxine, triiodothyronine, progesterone, and hydrocortisone) ...
Source: Aquatic Toxicology - October 7, 2017 Category: Toxicology Source Type: research

Treatment of Premenstrual Breakthrough of Depression With Adjunctive Oral Contraceptive Pills Compared With Placebo
Conclusions: Findings from this small randomized trial suggest that OCP augmentation of antidepressants may not be effective for treating premenstrual breakthrough of depression. Future studies should target women established to have hormonal sensitivity prior to antidepressant therapy and those with fewer lifetime depressive episodes. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - August 31, 2017 Category: Psychiatry Tags: Brief Reports Source Type: research

Different inhibitory potential of sex hormones on NNK detoxification in vitro: a possible explanation for gender-specific lung cancer risk
In this study, we examined the inhibition of NNK reduction to NNAL, the first and most important detoxication step of this tobacco-specific carcinogen. It is mediated by different carbonyl reductases of the SDR (CBR1 and 11 βHSD1) and AKR (AKR1B10, AKR1C1, AKR1C2 and AKR1C4) superfamilies. Inhibition constants of NNK reduction were determined with male (testosterone) and female (estradiol, progesterone) sex hormones and the contraceptives ethinylestradiol and drospirenone in A549 cells and with purified enzymes. (Source: Cancer Letters)
Source: Cancer Letters - July 22, 2017 Category: Cancer & Oncology Authors: Claudia Stapelfeld, Karolina-Theresa Neumann, Edmund Maser Source Type: research

Different inhibitory potential of sex hormones on NNK detoxification in  vitro: A possible explanation for gender-specific lung cancer risk
In this study, we examined the inhibition of NNK reduction to NNAL, the first and most important detoxication step of this tobacco-specific carcinogen. It is mediated by different carbonyl reductases of the SDR (CBR1 and 11 βHSD1) and AKR (AKR1B10, AKR1C1, AKR1C2 and AKR1C4) superfamilies. Inhibition constants of NNK reduction were determined with male (testosterone) and female (estradiol, progesterone) sex hormones and the contraceptives ethinylestradiol and drospirenone in A549 cells and with purified enzymes. (Source: Cancer Letters)
Source: Cancer Letters - July 22, 2017 Category: Cancer & Oncology Authors: Claudia Stapelfeld, Karolina-Theresa Neumann, Edmund Maser Tags: Original Article Source Type: research

Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. Effects on hemostasis.
Abstract INTRODUCTION: The pharmacodynamic effects of various combined oral estrogen-progestin combinations (COC) are examined for their components alone or in the various combined formulations. Special emphasis is given to products containing natural estrogens. Areas covered: Recent information on the effect of androgens, estrogens, progestins, as well as various COC combinations on the coagulation cascade will be reviewed aiming at providing an updated picture. The present article reviews hemostatic changes occurring during use of classic and modern combinations of estrogens (ethinyl estradiol, estradiol, estrad...
Source: Pharmacological Reviews - July 17, 2017 Category: Drugs & Pharmacology Authors: Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G Tags: Expert Rev Clin Pharmacol Source Type: research

Comparing the androgenic and estrogenic properties of progestins used in contraception and hormone therapy.
Abstract Progestins used in endocrine therapies bind to multiple steroid receptors and are associated with several side-effects. It is thus important to understand the relationship between steroid receptor cross-reactivity and the side-effect profile of progestins. In cell lines that express negligible levels of steroid receptors, we report for the first time the binding affinities, potencies and efficacies of selected progestins from different generations determined in parallel. We show that the progestins bind to the androgen receptor (AR) with similar affinities to each other and progesterone, while none bind e...
Source: Biochemical and Biophysical Research communications - July 12, 2017 Category: Biochemistry Authors: Louw-du Toit R, Perkins MS, Hapgood JP, Africander D Tags: Biochem Biophys Res Commun Source Type: research

Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three ‐arm randomized controlled trial
ConclusionsThe study fails to replicate a uniquely beneficial effect of continuous COC on PMD. Additional work is needed to understand the psychosocial context bolstering the placebo response in women with PMD. (Source: Depression and Anxiety)
Source: Depression and Anxiety - July 1, 2017 Category: Psychiatry Authors: Tory A. Eisenlohr ‐Moul, Susan S. Girdler, Jacqueline L. Johnson, Peter J. Schmidt, David R. Rubinow Tags: RESEARCH ARTICLE Source Type: research

Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control.
CONCLUSIONS: The present study shows that 15 mg estetrol combined with 3 mg DRSP is associated with a high-user acceptability and satisfaction, and with a favourable body weight control. PMID: 28641030 [PubMed - as supplied by publisher] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - June 22, 2017 Category: Reproduction Medicine Authors: Apter D, Zimmerman Y, Beekman L, Mawet M, Maillard C, Foidart JM, Coelingh Bennink HJT Tags: Eur J Contracept Reprod Health Care Source Type: research

Heme-Nitrosylated Hemoglobin and Oxidative Stress in Women Consuming Combined Contraceptives. Clinical Application of the EPR Spectroscopy.
CONCLUSION: This cross-sectional cohort study demonstrates that a decrease of HbNO measured by quantitative EPR in human venous erythrocytes is correlated with the development of endothelial dysfunction under CPs consumption, in parallel with increased vascular oxidative stress. PMID: 28392282 [PubMed - as supplied by publisher] (Source: Free Radical Biology and Medicine)
Source: Free Radical Biology and Medicine - April 6, 2017 Category: Biology Authors: Lobysheva II, van Eeckhoudt S, Rifahi A, Pothen L, Dei Zotti F, Beauloye C, Balligand JL Tags: Free Radic Biol Med Source Type: research

Sex hormones reduce NNK detoxification through inhibition of short-chain dehydrogenases/reductases and aldo-keto reductases in vitro
Publication date: Available online 28 February 2017 Source:Chemico-Biological Interactions Author(s): Claudia Stapelfeld, Edmund Maser Carbonyl reduction is an important metabolic pathway for endogenous and xenobiotic substances. The tobacco specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK, nicotine-derived nitrosamine ketone) is classified as carcinogenic to humans (IARC, Group 1) and considered to play the most important role in tobacco-related lung carcinogenesis. Detoxification of NNK through carbonyl reduction is catalyzed by members of the AKR- and the SDR-superfamilies which include AKR1B10,...
Source: Chemico Biological Interactions - March 1, 2017 Category: Biochemistry Source Type: research

Sex hormones reduce NNK detoxification through inhibition of short-chain dehydrogenases/reductases and aldo-keto reductases in vitro.
Abstract Carbonyl reduction is an important metabolic pathway for endogenous and xenobiotic substances. The tobacco specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK, nicotine-derived nitrosamine ketone) is classified as carcinogenic to humans (IARC, Group 1) and considered to play the most important role in tobacco-related lung carcinogenesis. Detoxification of NNK through carbonyl reduction is catalyzed by members of the AKR- and the SDR-superfamilies which include AKR1B10, AKR1C1, AKR1C2, AKR1C4, 11β-HSD1 and CBR1. Because some reductases are also involved in steroid metabolism, five...
Source: Chemico-Biological Interactions - February 28, 2017 Category: Molecular Biology Authors: Stapelfeld C, Maser E Tags: Chem Biol Interact Source Type: research

Cervicovaginal agenesis treated with modified Yang-Monti technique in two steps: Case report and literature review
Conclusion The two-steps modified Yang-Monti technique represents a safe alternative for the management of cervicovaginal agenesis. (Source: International Journal of Surgery Case Reports)
Source: International Journal of Surgery Case Reports - January 20, 2017 Category: Surgery Source Type: research

Pooled analysis of two randomized, open-label studies comparing the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinyl estradiol on bleeding patterns in healthy women
To obtain more precise and detailed information regarding the bleeding patterns of nomegestrol acetate (NOMAC)/17 β-estradiol (E2) and drospirenone/ethinyl estradiol (DRSP/EE) and to identify whether baseline demographic characteristics were associated with unscheduled bleeding, absent scheduled bleeding, or amenorrhea. (Source: Contraception)
Source: Contraception - December 21, 2016 Category: OBGYN Authors: Diana Mansour, Carolyn Westhoff, Uma Kher, Tjeerd Korver Tags: Original Research Source Type: research

Pharmacodynamics of combined estrogen-progestin oral contraceptives: Effects on metabolism.
Authors: Bastianelli C, Farris M, Rosato E, Brosens I, Benagiano G Abstract INTRODUCTION: The risk-benefit profile of any pharmacologic agent must be evaluated against risks connected with the events to be avoided. This is especially true in the case of hormonal contraception, not intended to combat a disease. Over the six decades during which their use has progressively expanded, the risk-benefit profile of combined oral contraceptives (COC) has substantially changed, with new combinations, dosages and mode of administration appearing on the market. Area covered: In a series of articles, recent information on the ...
Source: Expert Review of Clinical Pharmacology - December 17, 2016 Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research

Effect of hormone replacement therapy with the anti-mineralocorticoid progestin Drospirenone compared to tibolone on endothelial function and central haemodynamics in post-menopausal women
Drospirenone (DRSP) is an antialdosterone agent with progestogenic and antiandrogenic effects. This compound, has been recently used in combination with 17 ß-estradiol (E2) as hormonal therapy in postmenopausal women and has been shown to exert a significant antihypertensive effect in hypertensive post-menopausal women. Aim of the present study was to compare the effect of DRSP/E2 with those of Tibolone (T) on endothelial function, arterial stiffness, and lipid profile of early postmenopausal women naïve on post-menopausal hormonal therapy.Twenty-four women met the inclusion criteria and entered the study. (Sour...
Source: International Journal of Cardiology - November 8, 2016 Category: Cardiology Authors: Cristiana Vitale, Caterina Mammi, Marco Gambacciani, Novella Russo, Ilaria Spoletini, Massimo Fini, Maurizio Volterrani, Giuseppe M.C. Rosano Source Type: research

Myo-Inositol in the Treatment of Teenagers Affected by PCOS.
Conclusions. Administration of MI is a safe and effective method to prevent and correct metabolic disorders in teenagers affected by PCOS. With combination of MI and OCPs antiandrogenic effects are enhanced, negative impact of OCPs on weight gain is balanced, and metabolic profile is improved. PMID: 27635134 [PubMed] (Source: International Journal of Endocrinology)
Source: International Journal of Endocrinology - September 18, 2016 Category: Endocrinology Tags: Int J Endocrinol Source Type: research

Low-dose oral contraceptive-induced acute myocardial infarction.
CONCLUSION: Low-dose OCs may also be responsible for acute MI even in a very young female without any cardiovascular risk factors. Therefore, the clinicians should be aware of this mortal events during follow-up of the patient using OCs. PMID: 27608962 [PubMed - as supplied by publisher] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - September 9, 2016 Category: Reproduction Medicine Authors: Aslan AN, Süygün H, Sivri S, Keleş T Tags: Eur J Contracept Reprod Health Care Source Type: research

Reduced haemostatic effects with drospirenone-based oral contraceptives containing estetrol versus ethinyl estradiol
The effects of estetrol (E4), a natural foetal estrogen, combined with drospirenone (DRSP) were evaluated on plasma levels of Sex Hormone Binding Globulin (SHBG), angiotensinogen and 12 haemostasis markers. (Source: Contraception)
Source: Contraception - September 1, 2016 Category: OBGYN Authors: Cornelis Kluft, Yvette Zimmerman, Marie Mawet, Christine Klipping, Ingrid J.M. Duijkers, Jacoline Neuteboom, Jean-Michel Foidart, Herjan Coelingh Bennink Tags: Original research article Source Type: research

Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol
The effects of estetrol (E4), a natural fetal estrogen, combined with drospirenone (DRSP) were evaluated on plasma levels of sex hormone-binding globulin (SHBG), angiotensinogen and 12 hemostasis markers. (Source: Contraception)
Source: Contraception - September 1, 2016 Category: OBGYN Authors: Cornelis Kluft, Yvette Zimmerman, Marie Mawet, Christine Klipping, Ingrid J.M. Duijkers, Jacoline Neuteboom, Jean-Michel Foidart, Herjan Coelingh Bennink Tags: Original research article Source Type: research

Comparative study of the therapeutic effects of Drospirenone (DRSP, 3 mg) with Ethinyl Estradiol (EE, 20 mcg) pill with or without Metformin 500 mg in polycystic ovary syndrome (PCOS)
To compare the therapeutic effects of Drospirenone (DRSP,3 mg) with Ethinyl Estradiol (EE,20 mcg) pill with or without Metformin (500 mg) in polycystic ovary syndrome (PCOS) patients at 6 and 12 months of treatment. (Source: Fertility and Sterility)
Source: Fertility and Sterility - August 31, 2016 Category: Reproduction Medicine Authors: S.M. Bhattacharya, B. Biswas, A. Basu Tags: Poster session Source Type: research

A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
CONCLUSIONS: LNG-IUS 8 and EE/DRSP were associated with similarly high user satisfaction rates. However, LNG-IUS 8 users were significantly more likely to prefer to continue their contraceptive method post-study, indicating that a levonorgestrel intrauterine system is an appealing contraceptive option for young women. PMID: 27494570 [PubMed - as supplied by publisher] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - August 5, 2016 Category: Reproduction Medicine Authors: Borgatta L, Buhling KJ, Rybowski S, Roth K, Rosen K Tags: Eur J Contracept Reprod Health Care Source Type: research

Superior Mesenteric Vein Thrombosis Associated with Hormonal Contraceptive Use
A 44-year-old woman was admitted with a 7-day history of lower abdominal pain and nausea. Physical examination demonstrated tenderness in the lower abdomen without signs of peritonitis. There were no specific findings in the laboratory evaluation. She had a history of dysmenorrhea for 15 years and was taking a combined hormonal contraceptive containing 0.02 mg ethinyl estradiol and 3 mg drospirenone for 19 months. Contrast-enhanced computed tomography showed superior mesenteric vein thrombosis (SMVT). Systemic anticoagulant infusion was immediately administered and the symptoms disappeared within 2 days. The thrombus disap...
Source: Case Reports in Gastroenterology - June 6, 2016 Category: Gastroenterology Source Type: research

Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis
10.1080/09513590.2016.1183629Xu Zhao (Source: Gynecological Endocrinology)
Source: Gynecological Endocrinology - May 13, 2016 Category: Endocrinology Authors: Xu ZhaoXiao-Fang ZhangYang ZhaoXin LinNing-Yin LiGanesh PaudelQiong-Ying WangXiao-Wei ZhangXiu-Li LiJing Yu Source Type: research

Effects of drospirenone on adhesion molecule expression and monocyte adherence in human endothelial cells
Conclusions DRSP did not increase the expression of adhesion molecules or monocytoid cell adherence to endothelial cells, indicating that DRSP could reduce the risk of atherogenesis caused by MPA. These results suggest that DRSP may be an alternative to MPA in hormone replacement therapy. (Source: European Journal of Obstetrics and Gynecology and Reproductive Biology)
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - April 7, 2016 Category: OBGYN Source Type: research

Premenstrual flares of pyoderma gangrenosum controlled with use of a combined oral contraceptive and antiandrogen (ethinyl estradiol/drospirenone)
We report the case of a 34‐year‐old woman with chronic PG leg ulcers who was found to have recurring, premenstrual flares of PG. Her PG flares were controlled with the use of ethinyl estradiol/drospirenone. (Source: British Journal of Dermatology)
Source: British Journal of Dermatology - January 28, 2016 Category: Dermatology Authors: N. Jourabchi, S.M. Rhee, G.S. Lazarus Tags: Case Report Source Type: research

Pre‐menstrual flares of pyoderma gangrenosum controlled with use of a combined oral contraceptive and antiandrogen (Ethinyl Estradiol/Drospirenone)
This article is protected by copyright. All rights reserved. (Source: British Journal of Dermatology)
Source: British Journal of Dermatology - November 30, 2015 Category: Dermatology Authors: N. Jourabchi, S.M. Rhee, G.S. Lazarus Tags: Case Report Source Type: research

Pre-menstrual flares of pyoderma gangrenosum controlled with use of a combined oral contraceptive and antiandrogen (Ethinyl Estradiol/Drospirenone).
This article is protected by copyright. All rights reserved. PMID: 26616160 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - November 30, 2015 Category: Dermatology Authors: Jourabchi N, Rhee SM, Lazarus GS Tags: Br J Dermatol Source Type: research

Hormonal therapy with estradiol and drospirenone improves endothelium-dependent vasodilation in the coronary bed of ovariectomized spontaneously hypertensive rats.
This study investigated the effects of combined therapy with estrogen (E2) and DRSP on endothelium-dependent vasodilation of the coronary bed of ovariectomized (OVX) spontaneously hypertensive rats. Female spontaneously hypertensive rats (n=87) at 12 weeks of age were randomly divided into sham operated (Sham), OVX, OVX treated with E2 (E2), and OVX treated with E2 and DRSP (E2+DRSP) groups. Hemodynamic parameters were directly evaluated by catheter insertion into the femoral artery. Endothelium-dependent vasodilation in response to bradykinin in the coronary arterial bed was assessed using isolated hearts according to a m...
Source: Braz J Med Biol Res - November 20, 2015 Category: Research Authors: Borgo MV, Claudio ER, Silva FB, Romero WG, Gouvea SA, Moysés MR, Santos RL, Almeida SA, Podratz PL, Graceli JB, Abreu GR Tags: Braz J Med Biol Res Source Type: research

Comparison of two contraceptive pills containing drospirenone and 20μg or 30μg ethinyl estradiol for polycystic ovary syndrome
Conclusion Among patients with PCOS, an oral contraceptive pill containing 20μg EE has similar effects on androgen levels to those of a pill containing 30μg. Clinical Trial Registration Number: CTRI/2012/04/002571 (Source: International Journal of Gynecology and Obstetrics)
Source: International Journal of Gynecology and Obstetrics - November 7, 2015 Category: OBGYN Source Type: research

Comparison of two contraceptive pills containing drospirenone and 20μg or 30μg ethinyl estradiol for polycystic ovary syndrome
To compare the effects of 30μg and 20μg ethinyl estradiol (EE) among women with polycystic ovary syndrome (PCOS). (Source: International Journal of Gynaecology and Obstetrics)
Source: International Journal of Gynaecology and Obstetrics - November 5, 2015 Category: OBGYN Authors: Sudhindra M. Bhattacharya, Ayan Jha, Lipika DasMukhopadhyay Tags: Clinical article Source Type: research

Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.
Conclusions Combined with a progestin, E4 adequately suppresses ovarian activity, particularly when given at a dosage above 10 mg/day. Chinese Abstract -。 1835、,II,。24/4-,510/3;5,1020/150 μg;20 μg/3。13,,、、-。,。 109。。:20,/。。1721,。。 ,10/。 ;;;;. PMID: 26394847 [PubMed - in process] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - September 25, 2015 Category: Reproduction Medicine Authors: Duijkers IJ, Klipping C, Zimmerman Y, Appels N, Jost M, Maillard C, Mawet M, Foidart JM, Coelingh Bennink HJ Tags: Eur J Contracept Reprod Health Care Source Type: research